FDA Approves Olutasidenib for Relapsed or Refractory AML with a Susceptible IDH1 Mutation

From Diagnosis to Survivorship: Understanding AML and CLL From End to End

In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.